Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly, usually abbreviated AEDG and also spelled Epithalon. It has been studied in telomere biology, age-related endocrine measurements and cellular stress. The experiments include human-derived cells, lifetime mouse studies and a small human biomarker study; their outcomes give different answers. Human survival reports often cited in this area used the related pineal extract Epithalamin, which needs its own preparation label. The selected evidence has not established that AEDG prolongs human life.
Overview
Epitalon's development grew out of research on peptides in pineal-gland extracts. The pineal gland releases melatonin, a hormone involved in daily biological rhythms. Investigators developed a short, defined sequence to explore effects associated with the more complex preparation Epithalamin. The resulting tetrapeptide can be described chemically as AEDG; a gland extract contains a mixture whose identity extends beyond that sequence. Original tetrapeptide paper, extract context.
FDA's July 2026 identity table distinguishes the free peptide from its acetate form. The formula and mass shown below refer to the free peptide. Clinical interpretation also requires the actual material used in a study, because a paper's compound name may not specify its salt or manufacturing characteristics. FDA identity presentation.
Molecular profile
Forms and derivatives
Epitalon acetate
FDA's 2026 table lists H-Ala-Glu-Asp-Gly-OH·CH3CO2H, formula C14H22N4O9·C2H4O2 and molecular mass 450.40 g/mol for the acetate form. The chemical form used by each study remains important because many reports do not specify it.
Epithalamin (Epithalamine) pineal extract
Epithalamin is a pineal peptide preparation that informed development of the defined tetrapeptide. The human extract reports keep their original intervention label, including any accompanying Thymalin. Their mortality findings belong to those preparations.
Uses and research areas
Telomere studies ask how chromosome ends change in a cell culture. Lifetime animal experiments ask how survival and tumors vary in a specified strain and sex. Pineal and metabolic investigations examine melatonin, glucose and insulin, while mouse-oocyte experiments follow cell condition after ovulation. Each setting measures a different component of the broad aging question. Cell study, mouse lifetime study, primate study, oocyte study.
The small exact-peptide human study examined a melatonin metabolite and circadian-gene expression in night-shift workers. Those outcomes can investigate physiology without showing improvement in sleep, disability or survival. FDA's 2026 insomnia evaluation discussed that distinction when assessing the proposed use. Ivko et al., 2021, FDA evaluation.
Mechanism of action
Telomeres consist of repeated DNA and associated proteins at chromosome ends. They help cells distinguish a normal chromosome end from broken DNA. Telomerase maintains those repeats in some cells; its catalytic protein component is called hTERT. Gene expression, enzyme activity and telomere length are separate measurements, so researchers need to examine each when proposing a telomerase mechanism.
Cells can also maintain telomeres through alternative lengthening of telomeres, or ALT. This process uses recombination-related mechanisms and is found in some cancers. The 2025 Epitalon study examined both normal and breast-cancer cell models, making the distinction between telomerase and ALT relevant to its results. The study's proposed DNA/protein interactions remain mechanistic hypotheses; a complete causal pathway has not been demonstrated. Al-Dulaimi et al., 2025.
Melatonin findings raise a separate mechanism question. Djeridane and colleagues exposed pineal glands from young and old rats to the tetrapeptide in a controlled tissue experiment. Neither basal melatonin secretion nor secretion stimulated through a beta-adrenergic signal changed significantly. This negative experiment matters because it tests a direct effect on the gland. Endocrine changes observed in an intact animal could involve additional physiological steps. Djeridane et al., 2003.
Pharmacokinetics
The acquired primary studies did not establish a human route-specific concentration–time profile or a numerical elimination half-life for identified Epitalon material. FDA's 2026 evaluation likewise reported that pharmacokinetic and toxicokinetic studies had not been identified in its assessment. FDA evaluation.
No pharmacokinetic curve is supplied. A change in urinary melatonin metabolite follows a downstream hormone pathway and cannot describe the amount of Epitalon circulating in blood. Similarly, the duration of exposure in a cell culture gives an experimental time window rather than an elimination estimate.
Research findings
Telomere maintenance changed in human-derived cells
The 2003 study reported telomerase-related expression, enzyme activity and telomere elongation in telomerase-negative human fetal fibroblasts. Its endpoint concerned a cell population maintained in culture. The abstract's speculation about lifespan extended beyond what was measured in that experiment. Khavinson et al., 2003.
In the 2025 study, normal fibroblast and mammary epithelial cells showed telomerase-activity increases after three weeks. Two breast-cancer cell lines had longer telomeres after four days, but their telomerase activity did not increase significantly; ALT-related measurements increased instead. The results illustrate why an increase in hTERT expression alone cannot establish increased enzyme activity in every cell model. Al-Dulaimi et al., 2025.
A published correction replaced incorrect Figures 1–3, including their cell-model and exposure descriptions. Interpretation should use the corrected record. The correction belongs to this same experiment and adds no independent replication. Correction.
Mouse survival outcomes differed across the distribution
A lifetime study followed 54 female Swiss-derived SHR mice per group from three months of age until natural death. Mean lifespan did not change with Epitalon. The mean lifespan among the last ten percent of survivors increased by 13.3%, and maximum lifespan increased by 12.3%. Total spontaneous tumor incidence was unchanged. Anisimov et al., 2003.
Average survival and the longest-lived tail summarize different parts of the same distribution. The paper's result is more informative when both are retained: some tail outcomes improved while the whole-group mean remained unchanged. A separate senescence-accelerated mouse experiment reported a survival-tail effect in SAMP-1 animals, with no tumor-frequency improvement in that substrain. Its Epitalon and melatonin arms must also remain distinct. Anisimov et al., 2005.
Endocrine responses depended on the age and model
Goncharova and colleagues compared rhesus monkeys aged 20–27 years with animals aged six to eight. Older monkeys had lower nighttime melatonin and altered glucose/insulin measurements. After Epitalon exposure, the older animals showed higher nighttime melatonin and changes toward the younger animals' glucose-related pattern; the younger animals did not show these responses. Goncharova et al., 2005.
The monkey study measured responses in living animals, where many tissues and signals interact. The rat experiment exposed isolated pineal glands directly to Epitalon and found no significant change in melatonin release. This difference leaves the route to the monkey hormone response unresolved. Neither experiment tested improved sleep or longer survival in people.
A small human study measured melatonin metabolism
Ivko and colleagues' primary report describes increased urinary 6-sulfatoxymelatonin, a melatonin metabolite, and changes in circadian-gene expression after AEDG exposure. FDA's detailed account identifies 75 women aged 40–50, primarily night-shift workers; 40 with low baseline metabolite levels entered placebo or AEDG spray groups of 20 each. The observation period was 20 days. Primary report, FDA's trial account.
The reported urinary-metabolite increase was 1.7-fold. The study did not measure a clinical sleep endpoint, and FDA noted unclear blinding and absent safety reporting. This exact-peptide human evidence belongs in the record, with the outcome stated as melatonin metabolism. It does not answer whether the intervention treats insomnia or extends life.
Mouse oocytes provided a separate cellular-stress experiment
Yue and colleagues studied mouse oocytes aging after ovulation in culture over six, twelve and twenty-four hours. Selected exposure conditions reduced reactive oxygen species and spindle defects while improving mitochondrial and apoptosis-related measurements. Higher tested concentrations failed to reduce the reactive-oxygen signal, showing that the response was not uniform across the conditions examined. Yue et al., 2022.
These endpoints describe egg-cell condition during a short culture interval. Assessing their consequences for fertilization, embryo development and live birth would require outcomes beyond the cellular assays reported here.
Human extract reports retain their original preparation identity
The 2003 human mortality report names Epithalamin and Thymalin, separately or together. A later long-term report also identifies Epithalamine as a pineal peptide preparation. These results concern the materials named by their authors and cannot be assigned to AEDG on the basis of a shared research history. Khavinson and Morozov, 2003, Korkushko et al., 2006.
Another abstract discusses both Epithalamin and Epitalon in older monkeys and elderly people, reporting melatonin changes. The accessible account does not separate material-specific human groups, allocation or numerical outcomes well enough to reconstruct an AEDG clinical effect. It remains a retained source with that acquisition limitation. Korkushko et al., 2007.
Safety and tolerability
The selected exact-peptide evidence provides little information about long-term clinical harms. Telomere maintenance is relevant to both normal-cell function and malignant-cell persistence. The cancer-cell results therefore leave a consequential safety question that requires further investigation; they supply no estimate of cancer incidence in exposed people.
FDA's July 2026 assessment identifies no approved drug containing Epitalon free base or acetate and insufficient information to support safety and insomnia effectiveness. It also raises material-characterization and immunogenicity concerns. The current FDA compounding-risk page discusses aggregation and peptide-related impurities. The July slides present staff recommendations within a bulk-substance evaluation; that process is separate from approval of a finished drug. FDA 2026 evaluation, meeting presentation, current safety context.
What the research means
Epitalon has measurable biological effects in several models, but “aging” covers outcomes at very different scales. Telomere length describes chromosome biology, a melatonin metabolite describes a hormone pathway, and survival summarizes an organism's lifetime. The mouse studies themselves show why those scales should be kept visible: changes among the longest-lived animals coexist with unchanged average lifespan.
The next clinical questions need defined AEDG material, controlled comparators and outcomes such as sleep, function or survival, along with deliberate long-term harm assessment. Keeping the human biomarker result and related extract literature in view gives a fuller account without converting them into an established human longevity effect.
FAQs
Has Epitalon been shown to prolong human life?
The selected exact-peptide studies do not establish a human survival benefit. The human AEDG report examines a melatonin metabolite and gene expression. Long-term human mortality reports cited in this field identify the related extract Epithalamin, sometimes with Thymalin, so their preparation identity must remain visible.
Are Epithalon and Epithalamin the same thing?
Epithalon is a spelling of the defined AEDG tetrapeptide. Epithalamin names a pineal peptide preparation. The tetrapeptide's research history connects them, while each clinical result belongs to the material actually administered.
Why distinguish telomerase expression, activity and telomere length?
Gene expression measures instructions for a protein; an enzyme assay measures function; a length assay measures chromosome-end repeats. Those endpoints can diverge within the same cell model. Examining all three helps identify which biological explanation fits the observed result.
Did the lifetime mouse study increase average lifespan?
The Swiss-derived mouse study reported unchanged mean lifespan alongside favorable results in the longest-lived tail. Average survival and maximum survival answer different questions about the distribution. Both belong in an accurate account of the experiment.
Does the human melatonin study establish an insomnia benefit?
Its primary report describes a urinary melatonin metabolite and circadian-gene expression. A treatment claim for insomnia requires clinical sleep outcomes. FDA's 2026 assessment notes that the acquired human study did not measure those outcomes and did not report safety data.
What does the 2025 figure correction change?
The journal replaced incorrect versions of Figures 1–3. Readers should use the corrected publisher record when interpreting the cell results. The notice corrects the same study and is not another independent experiment.
Do the cancer-cell findings establish cancer risk in people?
They identify a biological question about telomere maintenance in malignant cells. The study did not follow exposed people for cancer incidence. Long-term clinical risk therefore remains an unanswered question rather than a quantified result.
Comparisons and related reading
Epithalamin belongs within this page as the extract preparation that informed Epitalon's research history. Its studies remain labelled by that identity. Humanin, MOTS-c and elamipretide offer separate approaches to cellular stress and mitochondrial function, with their own structures, models and clinical evidence.
References
The source list preserves all baseline studies and the original extract/mixed-preparation reports. The 2025 correction, negative pineal experiment, exact-peptide human biomarker paper and current official FDA assessment are included where they change interpretation.
Human fetal fibroblast cultures supplied the original telomerase-related observations. Speculation about organism lifespan exceeded the experiment's cellular endpoints.
Normal and malignant cell models showed differing telomere-maintenance responses. Increased hTERT expression did not imply increased telomerase activity in the breast-cancer lines.
The lifetime study reported unchanged mean lifespan and overall tumor incidence alongside favorable survival-tail endpoints.
Separate Epitalon and melatonin interventions produced substrain-dependent survival and tumor observations in senescence-accelerated mice.
Older rhesus monkeys showed changes in melatonin and glucose/insulin measurements, with no corresponding response in younger animals.
The oocyte culture study examined oxidative stress, spindles and mitochondrial condition over short intervals; responses varied across exposure conditions.
The correction replaces incorrect Figures 1–3 and supplies the appropriate cell and exposure descriptions for the same study.
The human report identifies Epithalamin and Thymalin preparations. It is retained for preparation context and is not counted as an AEDG survival trial.
The long-term human report concerns the pineal peptide preparation Epithalamine. Its material identity prevents reassignment of the findings to AEDG.
The abstract mentions both an extract and tetrapeptide across monkey and human settings. Material-specific human allocation and numerical outcomes remain unresolved in the acquired account.
The current official entry identifies possible immunogenicity from aggregation and peptide impurities and insufficient safety information for the proposed route.
The identity table labels free-peptide and acetate structures, formulas and masses. Staff reviewed the proposed insomnia use within a compounding-ingredient process.
The official assessment explains the human biomarker study's limits, identifies missing clinical safety/PK evidence and evaluates insomnia effectiveness.
The primary human report measures urinary melatonin metabolite and circadian-gene expression. It does not report a clinical survival or insomnia endpoint.
The isolated-gland experiment found no significant effect on basal or beta-adrenergically stimulated melatonin secretion in either age group.
Glossary
- Tetrapeptide
- A peptide containing four amino-acid residues.
- Telomere
- Repeated DNA and associated proteins that protect chromosome ends.
- Telomerase
- An enzyme complex that can add telomeric DNA repeats.
- hTERT
- The human telomerase catalytic protein component; gene expression and enzyme activity are distinct measurements.
- ALT
- Alternative lengthening of telomeres, a recombination-related maintenance process found in some cancer cells.
- Pineal gland
- A small endocrine gland that releases melatonin as part of daily biological timing.
- Circadian
- Following a biological rhythm of approximately 24 hours.
- 6-sulfatoxymelatonin
- A melatonin metabolite measured in urine to study melatonin production and metabolism.
- Oocyte
- An egg cell.
- Reactive oxygen species
- Reactive oxygen-containing molecules involved in signaling and, in excess, cellular injury.